Departments of Pharmacology and.
Department of Pharmacology, Vanderbilt University, Nashville, TN 37232.
Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10755-60. doi: 10.1073/pnas.1405190111. Epub 2014 Jul 7.
ML297 was recently identified as a potent and selective small molecule agonist of G-protein-gated inwardly rectifying K(+) (GIRK/Kir3) channels. Here, we show ML297 selectively activates recombinant neuronal GIRK channels containing the GIRK1 subunit in a manner that requires phosphatidylinositol-4,5-bisphosphate (PIP2), but is otherwise distinct from receptor-induced, G-protein-dependent channel activation. Two amino acids unique to the pore helix (F137) and second membrane-spanning (D173) domain of GIRK1 were identified as necessary and sufficient for the selective activation of GIRK channels by ML297. Further investigation into the behavioral effects of ML297 revealed that in addition to its known antiseizure efficacy, ML297 decreases anxiety-related behavior without sedative or addictive liabilities. Importantly, the anxiolytic effect of ML297 was lost in mice lacking GIRK1. Thus, activation of GIRK1-containing channels by ML297 or derivatives may represent a new approach to the treatment of seizure and/or anxiety disorders.
ML297 最近被鉴定为一种强效且选择性的 G 蛋白门控内向整流钾 (GIRK/Kir3) 通道小分子激动剂。在这里,我们表明 ML297 以需要磷脂酰肌醇-4,5-二磷酸 (PIP2) 的方式选择性地激活含有 GIRK1 亚基的重组神经元 GIRK 通道,但与受体诱导的、G 蛋白依赖性通道激活不同。GIRK1 的孔螺旋 (F137) 和第二跨膜 (D173) 结构域中两个独特的氨基酸被鉴定为 ML297 选择性激活 GIRK 通道所必需且充分的条件。对 ML297 的行为效应的进一步研究表明,除了其已知的抗惊厥功效外,ML297 还可降低焦虑相关行为,而无镇静或成瘾性。重要的是,在缺乏 GIRK1 的小鼠中,ML297 的抗焦虑作用丧失。因此,通过 ML297 或其衍生物激活包含 GIRK1 的通道可能代表治疗癫痫发作和/或焦虑障碍的新方法。